文献速递间质性肺疾病

Admilparant(LPA1拮抗剂)对肺纤维化疾病进展的影响

Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis.
PubMed 文献 · Chest · 2025-04-08

本研究为2期随机双盲安慰剂对照试验,纳入255例IPF和114例PPF患者,评估口服LPA1拮抗剂admilparant对疾病进展时间的影响。事后分析显示,60 mg剂量组在IPF和PPF队列中均延迟了26周内的疾病进展时间,支持进一步开展3期试验。

要点

  • 60 mg admilparant延迟IPF患者26周疾病进展时间(HR 0.54,95%CI 0.31-0.95)。
  • 60 mg admilparant延迟PPF患者26周疾病进展时间(HR 0.41,95%CI 0.18-0.90)。
  • 最常见首发进展事件为ppFVC相对下降≥10%,无死亡作为首发事件。

核心结论

  • 60 mg admilparant在IPF和PPF患者中均延迟了26周内的疾病进展时间,支持进一步开展3期试验。

研究设计与样本

  • 2期随机双盲安慰剂对照研究,IPF和PPF平行队列分别按1:1:1随机接受30 mg、60 mg admilparant或安慰剂每日两次,持续26周,允许背景抗纤维化治疗。
  • 共纳入255例IPF患者和114例PPF患者,疾病进展为事后分析,采用Kaplan-Meier法评估26周内首次进展事件时间。

主要发现

  • IPF队列基线ppFVC中位数为77.3%,PPF队列为64.7%。
  • 与安慰剂相比,60 mg admilparant延迟IPF患者疾病进展时间(HR 0.54;95%CI 0.31-0.95)。
  • 与安慰剂相比,60 mg admilparant延迟PPF患者疾病进展时间(HR 0.41;95%CI 0.18-0.90)。
  • 在基线ppFVC低于或高于中位数的亚组分析中观察到相似趋势。
  • 两个队列中最常见的首发事件为ppFVC相对下降≥10%,无死亡作为首发进展事件报告。

关键数值与推荐

  • 疾病进展定义为ppFVC相对下降≥10%、急性加重、全因住院和全因死亡的复合终点。

临床怎么用

  • 对于IPF或PPF患者,admilparant 60 mg每日两次可能延迟疾病进展,但需3期试验进一步验证。

局限性

  • 疾病进展分析为事后分析,非预设主要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are chronic fibrosing interstitial lung diseases associated with irreversible loss of lung function and early mortality. Admilparant (BMS-986278) is an oral lysophosphatidic acid receptor 1 antagonist under development for treatment of IPF and PPF. RESEARCH QUESTION: How does admilparant affect time to disease progression in patients with IPF or PPF? STUDY DESIGN AND METHODS: In a phase 2, randomized, double-anonymized, placebo-controlled study, parallel cohorts of patients with IPF or PPF were randomized separately 1:1:1 to receive 30 mg admilparant, 60 mg admilparant, or placebo twice daily for 26 weeks; background antifibrotics were allowed. The effect of admilparant vs placebo on time to disease progression was assessed post hoc. Disease progression was defined as a composite of relative decline of ≥ 10% in percent predicted FVC (ppFVC), acute exacerbation, all-cause hospitalization, and all-cause mortality. Subgroup analyses were performed based on median ppFVC at baseline. A Kaplan-Meier product-limit approach assessed time to first event of disease progression over 26 weeks. RESULTS: In total, 255 patients with IPF and 114 patients with PPF were included. Median ppFVC at baseline was 77.3% and 64.7% in the IPF and PPF cohorts, respectively. Treatment with 60 mg admilparant delayed time to disease progression over 26 weeks compared with placebo in both cohorts of patients (IPF: hazard ratio, 0.54; 95% CI, 0.31-0.95; PPF: hazard ratio, 0.41; 95% CI, 0.18-0.90). A similar trend was observed in the subgroup analysis of patients with ppFVC at baseline either below or above the median value. In both cohorts, the most frequent first event was relative decline of ≥ 10% in ppFVC; no deaths were reported as first progression events. INTERPRETATION: These findings support further evaluation of admilparant as a therapeutic option for patients with IPF or PPF in phase 3 trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04308681; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kreuter M, Maher TM, Wuyts WA, et al. Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. Chest. 2025. PMID: 40210090. doi:10.1016/j.chest.2025.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。